Argenx
Argenx SE, a leading biotechnology company headquartered in the Netherlands, is at the forefront of developing innovative therapies for severe autoimmune diseases and cancer. Founded in 2008, Argenx has made significant strides in the industry, particularly with its proprietary antibody engineering platform, which enables the creation of unique therapeutic candidates. The company’s flagship product, efgartigimod, has garnered attention for its potential to transform treatment paradigms in conditions like myasthenia gravis. With a strong presence in Europe and North America, Argenx has established itself as a key player in the biopharmaceutical sector, recognised for its commitment to advancing patient care through cutting-edge science and strategic partnerships.
DitchCarbon Score
How does Argenx's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Argenx's score of 41 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Argenx's reported carbon emissions
In 2024, Argenx reported total carbon emissions of approximately 231,769,000 kg CO2e. This figure includes 3,788,000 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources. Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling, amounted to about 534,000 kg CO2e (market-based). The majority of their emissions, approximately 227,447,000 kg CO2e, fall under Scope 3, which includes emissions from the entire value chain, such as purchased goods and services (about 183,781,000 kg CO2e) and business travel (approximately 13,340,000 kg CO2e). In 2023, Argenx's total emissions were reported at about 433,353,000 kg CO2e, with Scope 1 emissions at 378,000 kg CO2e and Scope 2 emissions at approximately 189,000 kg CO2e (market-based). The Scope 3 emissions for that year were significantly higher, at around 432,786,000 kg CO2e, primarily driven by purchased goods and services. Currently, Argenx has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to the Science Based Targets initiative (SBTi). The company’s emissions data is not cascaded from any parent organization, and all reported figures are directly attributed to Argenx SE. Overall, Argenx's emissions profile highlights the significant impact of Scope 3 emissions, underscoring the need for comprehensive strategies to address carbon footprints across their supply chain and operational activities.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 378,000 | 0,000,000 |
| Scope 2 | 189,000 | 000,000 |
| Scope 3 | 432,786,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Argenx is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
